Please assess the completion status of the following clinical trial:

Trial Title: RCT for Women With a Persisting Pregnancy of Unknown Location

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Female with a persisting pregnancy of unknown location:~   1. A pregnancy of unknown location is defined as a women with a positive pregnancy test but no definitive signs of pregnancy in the uterus or adnexa on ultrasound imaging (Ultrasound must be performed within 7 days prior to randomization)~  2. Persistence of hCG is defined as 3 serial hCG values over 4-14 days or 2 serial hCG values over 7-14 days, showing less than 30% rise, or less than 30% fall between the first and last value. (This abnormal pattern of serial hCG confirms that the gestation is nonviable.)~2. Patient is hemodynamically stable, hemoglobin greater than 10 mg/dL,~3. Greater than or 18 years of age~Exclusion Criteria:~1. Hemodynamically unstable in need of acute treatment~2. Most recent hCG greater than 5000 IU/mL~3. Patient obtaining care in relation to a recently completed pregnancy (delivery, spontaneous or elective abortion),~4. Diagnosis of gestational trophoblastic disease,~5. Subject unwilling or unable to comply with study procedures,~6. Presence of clinical contraindications for treatment with methotrexate (ACOG guidelines, Appendix B),~7. Prior medical or surgical management of this gestation.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Uterine evacuation, then MTX for some (Type: ACTIVE_COMPARATOR): Subjects will undergo a uterine evacuation. If hCG levels do not sufficiently decrease after the uterine evacuation, the subject will be treated with methotrexate. If hCG levels do sufficiently decrease after the uterine evacuation, no further treatment is required.
- Empiric treatment with MTX for all (Type: ACTIVE_COMPARATOR): Subjects will be treated with methotrexate, receiving one dose on day 0 and a subsequent dose on day 4. Additional doses will be administered as needed based on hCG levels.
- Expectant Management (Type: ACTIVE_COMPARATOR): Subjects will have their PPUL expectantly managed using serum hCG monitoring.

Based on this trial design, predict the completion outcome and termination type (if applicable).